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BACKGROUND: Prior studies suggest neurodevelopmental impacts of polybrominated diphenyl ethers (PBDEs), but few have examined diagnosed de-
velopmental disorders.
OBJECTIVES: Our aim was to determine whether prenatal exposure to brominated flame retardants (BFRs) is associated with autism spectrum disorder
(ASD) or intellectual disability without autism (ID).
METHODS: We conducted a population-based case–control study including children with ASD (n=545) and ID (n=181) identified from the
California Department of Developmental Services and general population (GP) controls (n=418) from state birth certificates. ASD cases were
matched to controls by sex, birth month, and birth year. Concentrations of 10 BFRs were measured in maternal second trimester serum samples stored
from routine screening. Logistic regression was used to calculate crude and adjusted odds ratios (AOR) for associations with ASD, and separately for
ID, compared with GP controls, by quartiles of analyte concentrations in primary analyses.
RESULTS: Geometric mean concentrations of five of the six congeners with ≥55% of samples above the limit of detection were lower in mothers of
children with ASD or ID than in controls. In adjusted analyses, inverse associations with several congeners were found for ASD relative to GP (e.g.,
quartile 4 vs. 1, BDE-153: AOR=0:56, 95% CI: 0.38, 0.84). When stratified by child sex (including 99 females with ASD, 77 with ID, and 73 with
GP), estimates were consistent with overall analyses in boys, but in the opposite direction among girls, particularly for BDE-28 and -47 (AOR=2:58,
95% CI: 0.86, 7.79 and AOR=2:64, 95% CI: 0.97, 7.19, respectively). Similar patterns overall and by sex were observed for ID.
CONCLUSIONS: Contrary to expectation, higher PBDE concentrations were associated with decreased odds of ASD and ID, though not in girls. These
findings require confirmation but suggest potential sexual dimorphism in associations with prenatal exposure to BFRs. https://doi.org/10.1289/
EHP1079
Introduction
Autism spectrum disorder (ASD) is defined according to deficits
in social communication and presence of restricted behaviors.
This neurodevelopmental condition currently affects about 1 in
68 U.S. children, and is approximately four times more common
in males than females (Christensen et al. 2016). The etiology of
ASD remains largely unexplained; however, evidence supports
the influence of both genetic and environmental factors acting in
the prenatal period (Rodier 2000; Newschaffer et al. 2007). We
recently reported that prenatal exposure to certain polychlori-
nated biphenyl (PCBs) congeners was positively associated with
odds of ASD (Lyall et al. 2017). Like PCBs, polybrominated di-
phenyl ethers (PBDEs) and the chemical 2,20,4,40,5,50-hexabro-
mobiphenyl (BB-153), known as brominated flame retardants
(BFRs), are another class of endocrine-disrupting chemicals
(EDCs). Developmental exposure to BFRs, and EDCs in general,
has emerged as a suspected risk factor for ASD (Hertz-Picciotto
et al. 2011; Grandjean and Landrigan 2014; Lyall et al. 2014)
given known influences of hormone disruptions on brain develop-
ment (de Escobar et al. 2004; Morreale de Escobar et al. 2004;
Costa and Giordano 2007).
Although many BFRs have been phased out of use in the
United States, levels of these chemicals are still detected in human
blood samples due to their lipophilic nature and the continued ex-
istence of products such as furniture and plastics that contain them
(Hites 2004; Sjödin et al. 2004, 2014). Developmental concerns
arose following evidence in animal studies that BFRs at levels
within the range of high exposure in humans in recent decades
impact brain development and neurodevelopmental outcomes rele-
vant to ASD (Eriksson et al. 2001, 2002; Birnbaum and Staskal
2004; Costa and Giordano 2007; Suvorov et al. 2009). Further,
BFRs can transfer from maternal to fetal circulation in humans
(Mazdai et al. 2003; Frederiksen et al. 2010; Gómara et al. 2007;
Chen et al. 2014b), have been associated with thyroid hormone in
humans (Chevrier et al. 2010, 2011; Vuong et al. 2015) and
markers of immune function in humans and animal studies
(Ashwood et al. 2009; Liu et al. 2012), and could suggest potential
pathways through which these chemicals may influence fetal neu-
rodevelopment and ASD.
To our knowledge, no published studies to date have consid-
ered prenatal BFR levels in association with risk of ASD diagno-
ses specifically. However, gestational exposure in some human
epidemiological studies has been shown to be associated with
evidence of cognitive deficits, behavioral impairments, and atten-
tion problems (Herbstman et al. 2010; Dingemans et al. 2011;
Czerska et al. 2013; Chen et al. 2014a; Herbstman and Mall
2014; Cowell et al. 2015; Sagiv et al. 2015). Only one study
(Braun et al. 2014) has examined prenatal BFR levels in associa-
tion with offspring autistic traits as measured by the Social
Responsiveness Scale (Constantino and Gruber 2005). This cohort
study including 175 women reported evidence of positive, inverse,
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and null associations, depending on the congener assessed. Another
investigation, a population-based case–control study including 100
children, did not find significant differences in current PBDE levels
between children with ASD (n=51) and those with typical devel-
opment (n=23) (Hertz-Picciotto et al. 2011). However, measure-
ments were conducted in childhood (mean age 3.7 y), after
diagnosis, and thus may not represent the suspected developmen-
tally relevant period of exposure during prenatal neurodevelopment
(Rodier et al. 1996; Rice and Barone 2000; Rodier 2000).
In order to address these prior limitations and examine the
potential role that prenatal exposure to BFRs plays in risk of
ASD and in broader adverse neurodevelopment as defined by in-
tellectual disability (ID), we used data from a large population-
based case–control study in California. Given the suggested neu-
rodevelopmental toxicity of BFRs, we hypothesized that higher
levels of BFRs would be found in prenatal samples from mothers
of children with ASD relative to mothers of control children
without developmental delays, and that similar associations may
be seen with ID. Given evidence for endocrine disruption activity
and suggested sexually dimorphic effects of BFRs on neurobeha-
vioral outcomes from animal work (Lilienthal et al. 2006; Faass
et al. 2013), we were also interested in exploring potential sex
differences in risk of ASD and ID associated with prenatal BFR
exposure.
Methods
Study Population
We used data from the Early Markers for Autism (EMA) study to
address these questions. Details of EMA methods have been pre-
viously described in an earlier paper (Croen et al. 2008). Briefly,
EMA is a population-based case–control study designed to identify
biologic markers of autism using archived prenatal and newborn
blood samples from California state-wide screening programs. The
EMA study sample was drawn from the population of live-born
children in three counties from Southern California (Orange, San
Diego, and Imperial) in 2000–2003 who participated in the newborn
screening program and whose mothers enrolled in the State’s
Prenatal Expanded Alpha-fetoprotein Screening Program (XAFP).
Approximately 70% of women in California participate in prenatal
screening, with samples stored from 7–10 diverse counties through-
out the state. Newborn screening is mandatory in the state of
California. Following selection (further described below), children
were then linked to the prenatal specimen archive to identify those
for whom prenatal specimens were available for inclusion in this
study. Only mother–child pairs with live birth records linked to
archived prenatal and newborn specimens were eligible for inclu-
sion in EMA.
Diagnostic information for the study population was obtained
from the California Department of Developmental Services
(DDS), which provides services to individuals with substantial
disabilities—including autism, intellectual disability, and other
developmental disabilities. Further information on the DDS can
be found on their website (http://www.dds.ca.gov). DDS data
were linked to eligible live birth records for the study region to
identify, based on DDS service codes: children with ASD or chil-
dren with intellectual disability/developmental delay without au-
tism (mental retardation of unknown etiology codes) (ID). GP
controls were identified by randomly sampling from eligible birth
certificates among strata of matching factors, excluding DDS cli-
ents. Individuals with Down syndrome were excluded from all
study groups. At the time of data linkage with DDS in 2007 and
2009, children would have been between 4.5 and 9 y old; the ma-
jority of cases were between 4.5 and 7 y old when identified. GP
controls were originally individually matched to ASD cases on
sex, birth month, and birth year. (However, matched analyses
were not used as primary analyses here in order to include those
individuals originally identified as ID but whom, following clinician
review, were found to meet ASD criteria; further described below
in “Diagnostic Verification”). Study activities were approved by the
institutional review board at Kaiser Permanente and by the
California State Committee for the Protection of Human Subjects.
Informed consent was not required for the EMA study, given that
consent forms for the XAFP Screening program were distributed at
the time of the blood collection, which stipulated that specimens
and results from prenatal testing could be used for legitimate
research purposes given appropriate IRB approval.
Diagnostic Verification
Final case status of children with ASD and children with ID was
determined by expert clinical review of diagnostic and clinical
data abstracted from DDS records, using an approach based on
national surveillance methodology (Yeargin-Allsopp et al. 2003).
A final diagnostic classification of ASD was given if DSM-IV-
TR criteria were met; in our analytic sample with BFR measure-
ments, 413 children originally identified as ASD in DDS met
these diagnostic criteria. Additionally, a total of 132 individuals
originally identified as ID in DDS were reclassified as ASD fol-
lowing expert review of abstracted data. ASD cases were further
qualified by presence/absence of intellectual disability (defined as
for ID, but in the presence of ASD). Final classification of ID (in-
tellectual disability without autism) was based on standardized
test score results found in records (composite developmental/cog-
nitive score <70) in the absence of meeting ASD criteria.
Specimens and Measurements
After screening was completed at the regional laboratory, newborn
dried blood spots were routinely freezer archived, as has been done
statewide since 1982, and maternal blood from Southern California
was freezer archived as part of the California Department of Public
Health’s Project Baby’s Breath. Maternal blood specimens were
collected typically between 15 and 20 wk gestation (median: 16 wk,
range 7–25 wk) in serum separator tubes by obstetrical care service
providers and underwent XAFP testing within 7 d of collection at a
central laboratory (median time= 3 d). After 1–2 d of refrigeration,
leftover serum and cell pellet specimens were stored at −20C.
A total of 10 BFRs were measured in maternal serum samples
(BB153, BDEs 17, 28, 47, 66, 85, 99, 100, 153, 154) at the Centers
for Disease Control and Prevention. Determination of target analy-
tes was performed by gas chromatography–isotope dilution high re-
solution mass spectrometry (GC-IDHRMS), employing a Double
Focusing Sector (ThermoFinnigan DFS, Bremen, Germany) instru-
ment (Jones et al. 2012). The measurements were performed in two
batches March–April, 2012 (N=276) and August–December, 2013
(N=1,080), that is, up to 13 y after the collection of the serum
samples between year 2000 and 2003. However, serum pools
have been shown to be stable over multiple years, as is expected
for persistent organic pollutants such as PBDEs (Sjödin et al.
2004; Turyk et al. 2010). Hence, it can be assumed that no appre-
ciable degradation of target analytes has occurred during the stor-
age of the samples for close to a decade. Concentrations of the
BFRs were reported as ng/g lipid weight (weight of serum lipids)
after background subtraction (background refers to the contami-
nation of blank samples in the same run as the unknowns). All
concentration data were corrected for the average amount present
in blank samples, and three blanks were included in every set of
30 samples. A variable amount of serum was available (median
1:2 g; range: 0:1–2:1 g); due to this, a variable limit of detection
was applied proportional to the serum amount used, that is,
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detection limit (picograms) divided with the available serum
amount (grams). In order to prevent biasing the data due to
higher LODs at lower amount of available serum, we censored
the data based on detection frequency of each individual conge-
ner. The method used to censor the data was to calculate the
detection frequency for all analytes by categorized available se-
rum amounts, that is, <0:2; 0:2 to<0:4; 0:4 to<0:6; and ≥0:6 g.
If the detection rate was less than 60% in a serum amount cate-
gory with <0:6 g of serum, the data was categorized as nonrep-
ortable in that category and any lower serum amount category.
One hundred five samples in the full EMA study (7.7%) had se-
rum amounts less than 0:6 g.
Statistical Analyses
These analyses included singleton births with final case status
(see “Diagnostic Verification”) and BFR measurements available.
Individuals missing all biomarker measurements (due to insuffi-
cient sample; n=5), and individuals censored due to laboratory
error (failure of automation system; n=33) were excluded, leav-
ing a total of 1,144 individuals. This number includes 545 children
with ASD (287 with intellectual disability, 221 without intellectual
disability, and 37 for whom we did not have information available
to make an intellectual disability classification), 181 children with
ID but not autism, and 418 GP control children.
For each of the BFRs measured, the percentage of the study
group with levels above the limit of detection (LOD) was calcu-
lated. We used a cutoff detection rate of at least 55% of the study
population with values above the LOD for selection of congeners
with sufficient number of study participants with detectable val-
ues for further analysis. Among those congeners meeting this
detection rate, individual measurements <LOD were replaced
with the LOD divided by the square root of 2 (Axelrad et al.
2009; Sjödin et al. 2014), although alternative methods for imput-
ing values below the LOD were also utilized (see “Sensitivity
Analyses” below). In addition to examining the individual conge-
ners, we created a variable for combined BFR exposure by sum-
ming the individual concentrations of congeners (BB153, BDE-
28, 47, 99, 100, and 153) meeting our detection rate cutoff. Other
sums explored included BDE congeners only (e.g., not including
BB153), including only those congeners detected in at least 60%
of the study population (which removed BDE-28 from the sum),
and high (BDE-100 and -153) or low (BDE-28 and -47) bromi-
nated congener sums.
Descriptive statistics were compared between the ASD, ID,
and GP groups, and correlation coefficients between congeners
were calculated. Geometric mean concentrations were calculated,
and were also compared by diagnostic group and potential con-
founders. Potential covariates (listed below) were selected on the
basis of a priori associations with ASD and/or the BFRs, and
obtained from birth certificates or XAFP screening program
records.
In order to examine the relationship between concentrations
of BFRs and ASD, examine potential dose response, and account
for potential nonlinearity in the association, we examined the ex-
posure–outcome relationship using a) quartiles of chemical con-
centrations or their sums (based on the control distribution), b)
continuous concentrations, examining odds associated with a 10-
fold BFR increase, and c) cubic splines to evaluate potential nonli-
nearity in the association and allow for flexibility in the dose–
response relationship (Durrleman and Simon 1989; Govindarajulu
et al. 2007). For continuous analyses of 10-fold changes in expo-
sure levels, continuous variables of BFR concentration (with val-
ues <LOD replaced as described) were divided by 10, so that
corresponding beta coefficients would have the interpretation of a
10-unit change in exposure level. Secondary analyses also
examined alternate categorizations (e.g., deciles, 95th and 5th per-
centiles). As stated above, matching was broken in primary analy-
ses in order to include all final ASD cases with biomarker
measurements. Logistic regression was used to obtain crude
(adjusted only for matching factors) and multivariable adjusted
odds ratios (OR) and 95% confidence intervals (CI) for the associ-
ation between the categorized (quartiles) congeners and ASD in
comparison to GP controls. All final models included (variables
obtained from birth records unless noted) the study matching fac-
tors (child sex, birth month, and birth year—the latter modeled as
ordinal variables), maternal age (continuous), maternal race/eth-
nicity (in categories), maternal weight at time of sample collection
(continuous; obtained from screening program records), parity (as
0 for no prior live births or 1 for one or more prior live births), and
maternal education (in categories). Categorical variables were
modeled using the “class” statement in SAS (SAS Institute Inc.).
Separate categories were used for missing covariate data (∼ 1% or
less of each study group for maternal education and race/ethnic-
ity). Adjustment for child gestational age (obtained from screening
records), and child birth weight (continuous), paternal age (contin-
uous), and maternal birthplace (as in the United States, Mexico, or
outside the United States or Mexico) did not impact results (e.g.,
did not change the estimate <10%, a criterion used across analyses
for deeming whether results differed; furthermore, gestational age
and birthweight may be on the causal pathway); thus, these covari-
ates were not included in final models. Secondarily, we also
explored adjustment for PCBs, which were associated with ASD
in a previous analysis of the same study population (Lyall et al.
2017). Tests of trend were conducted using an ordinal variable
defined according to the median analyte level of each quartile,
with significance determined by a Wald test (p<0:05) in the
adjusted models. We also examined whether odds of ASD may
differ according to presence of co-occurring intellectual disability
by modeling ASD with and without intellectual disability sepa-
rately, relative to GP controls. Separately, we also examined odds
of ID relative to GP controls in parallel analyses.
Stratified analyses were conducted to examine potential effect
modification of the association between BFRs and ASD by child
sex, given suggestions of potentially sexually dimorphic effects
from animal studies (Daniels et al. 2010; Leonetti et al. 2016;
Grether et al. 2009; Shelton et al. 2010). Tests of interaction were
conducted using a Wald test for the product of sex by the conge-
ner (using the median-value quartile variable; again, p<0:05 was
used to define statistical significance).
Sensitivity Analyses
A number of sensitivity analyses were conducted to assess
robustness of results. First, we examined the effect of excluding
from the ASD group individuals originally identified as ID but
classified as ASD following expert review (n=132). Conditional
logistic regression analyses (e.g., stratified by matching factors
rather than adjusting for them as in primary logistic regression
analyses) were conducted within the subset of matched ASD-GP
pairs (n=826, including 413 pairs) to examine the impact of
breaking the matching and including reclassified ID cases in the
ASD group in primary analyses. We also considered alternate
strategies for replacing values <LOD (for congeners detected in
at least 55% of samples); these included using lab-read values for
low sample volumes originally censored to <LOD (uncensored
data) and multiple imputation using SAS PROC MI (SAS 2015).
Data used to impute missing values included all chemicals assessed,
diagnostic status (ASD, ID, and GP), and covariates previously
mentioned as potential confounders. We also examined whether
removing those individuals with values <LOD (rather than imput-
ing their values as in primary analysis) altered results. Finally, we
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tested whether adjustment for genetic ancestry of mothers, as meas-
ured by principal components (PCs) derived from genome-wide
association study (GWAS) data, altered results. Details of GWAS
and ancestry analyses in EMA are further described in another
publication (Traglia et al. 2017); briefly, genome-wide multi-
dimensional scaling (MDS) analysis was carried out on high-quality
markers genotyped in maternal cell-pellet samples stored from the
XAFP and in newborn samples collected through newborn screen-
ing, using a pairwise distance genomic matrix and the multi-
dimensional scale functions implemented in PLINK software
(Purcell et al. 2007) (–cluster and –mds plot). The resulting maternal
and fetal genetic matrices included 10 PCs that summarized the
genetic distance between each maternal and neonatal sample. The
top two PCs, which accounted for the majority of variation, were
used in ancestry-adjusted models here. PC-adjusted models included
other potential confounders described above, with the exception
of race/ethnicity, which would be accounted for by the PCs.
Adjustment for PCs was not conducted for the ID to GP compari-
sons because genetic information was available only for the ASD
and GP groups.
Results
Comparing basic characteristics of the study groups, the mean
maternal age was higher, and there was a greater proportion of
non-Hispanic whites and more highly educated mothers, in the
ASD group compared with the ID or GP groups, whereas higher
parity, lower maternal education, Hispanic ethnicity, maternal
birth place in Mexico, use of a government insurance program,
and higher proportion of preterm and low-birth-weight babies
were all more common in the ID group relative to the others
(Table 1). The higher proportion of males in the ASD and GP
groups is a result of an original design feature of the EMA study,
wherein cases and controls were matched on sex (as well as birth
month and birth year). Of the 10 BFR congeners measured, 6
(BB153, BDE-28, -47, -99, -100, and -153) met our detection
rate cutoff. In general, congener detection rates were similar
across diagnostic groups, though rates were significantly lower in
ASD cases than GP controls for BDE-85 (35% vs. 44%), -99
(92% vs. 96%), and -100 (93% vs. 96%) (Table 2). Levels of con-
geners measured here were in line with ranges reported for all
females in the National Health and Nutrition Examination Survey
(survey years 2003–2004, partially overlapping with EMA birth
years), though geometric means were somewhat lower than those
reported from a sample of U.S. pregnant women during the same
time period (Woodruff et al. 2011) (see Table S1).
Geometric mean concentrations of lipid-adjusted BFRs were
lower in ASD cases than GP controls for five of the six of the
congeners detected in ≥55% of samples (all BDE congeners), as
well as for the sum of these six congeners (Table 3). Levels in
Table 1. Characteristics of the study population by diagnostic group.
Characteristic
ASD
(n=545)
ID
(n=181)
GP
(n=418)
Maternal age [mean (SD)] 29.9 (5.6) 27.2 (6.3) 28.7 (5.4)
Paternal age [mean (SD)] 35.7 (14.6) 36.9 (21.2) 34.0 (14.2)
Total no. live births [mean (SD)] 1.8 (0.9) 2.3 (1.5) 2.1 (1.0)
Parity [n (%)]a
Primiparous 247 (45%) 62 (34%) 159 (38%)
Multiparous 298 (55%) 119 (66%) 259 (62%)
Maternal age categories [n (%)]
<35 y 442 (81%) 159 (88%) 366 (88%)
≥35 y 103 (19%) 22 (12%) 52 (13%)
Maternal weight at sample collection [n (%)]
≤127 lbs 143 (26%) 33 (18%) 110 (26%)
128–145 lbs 136 (25%) 41 (23%) 114 (27%)
146–169 lbs 135 (25%) 52 (29%) 95 (23%)
≥170 lbs 131 (24%) 55 (30%) 99 (24%)
Maternal birth place [n (%)]
United States 272 (50%) 79 (44%) 202 (48%)
Mexico 131 (24%) 84 (46%) 128 (31%)
Other 142 (26%) 18 (10%) 88 (21%)
Maternal race/ethnicity [n (%)]
Non-Hispanic white 192 (35%) 32 (18%) 138 (33%)
Asian 82 (15%) 9 (5%) 45 (11%)
Black, Pacific Islander and other 48 (9%) 13 (7%) 35 (8%)
Hispanic 218 (40%) 126 (70%) 197 (47%)
Missing 5 (1%) 1 (0.6%) 3 (0.7%)
Maternal education [n (%)]
Less than high school 97 (18%) 76 (42%) 102 (24%)
High school 118 (22%) 50 (28%) 113 (27%)
Some college/college degree 222 (41%) 42 (23%) 143 (34%)
Post-graduate 100 (18%) 11 (6%) 56 (13%)
Missing 8 (1.5%) 2 (1%) 4 (1%)
Insurance status at delivery [n (%)]
Self and other 19 (3%) 7 (4%) 18 (4%)
Private insurance 289 (53%) 49 (27%) 207 (50%)
Government program 237 (43%) 125 (69%) 193 (46%)
Child sex
Male 446 (82%) 104 (57%) 345 (83%)
Female 99 (18%) 77 (43%) 73 (17%)
Child preterm (<37 wk) [n (%)] 66 (13%) 37 (22%) 44 (11%)
Child low birth weight (<2,500 g) [n (%)] 42 (8%) 40 (22%) 21 (5%)
Note: ASD, autism spectrum disorder; GP, general population controls; ID, intellectual disability/developmental delay without autism.
aDefined according to total live births.
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the ID group were lower than levels in the GP controls for all
congeners detected in ≥55% of samples. Comparing ID to ASD,
levels in the ID group were higher for BDE-47, -99, and -100 than
levels in the ASD group. With the exception of BB153, all conge-
ners demonstrated strong and significant correlations between one
another (r 0.54–0.99, p-values <0:001; see Table S2).
When examining odds of ASD according to quartiles, individ-
uals in higher quartiles of all BFR congeners, except BB153, had
reduced odds of ASD relative to those in the lowest quartile, in
analyses adjusted for the matching factors only (Model 1) and
adjusted analyses (Model 2) (Table 4). In adjusted models, indi-
viduals in the third-fourth quartiles of levels of BDE-47, -99, and
-100 had approximately a 30% reduction in odds of having a
child with ASD; of these, only BDE-100 demonstrated a signifi-
cant inverse association with ASD odds (for quartiles 2 and 3,
though estimates were nearly identical across quartiles 2–4).
Slightly stronger inverse associations were observed for the high-
est quartiles of BDE-153 (AOR=0:56; 95% CI: 0.38, 0.84) as
well as the BFR sum (AOR=0:64; 95% CI: 0.44, 0.93). Tests of
trend of BDE-153 and the combined BFR were also statistically
significant, though the pattern of estimates across quartiles was not
monotonic. Additional adjustment for gestational age, maternal
country of birth, child birth weight, PCB levels, and other covari-
ates available including paternal age and insurance status did not
impact results (data not shown). Exploring other sums of conge-
ners (as detailed in “Methods”) yielded similar estimates as the
sum of congeners meeting our detection rate cutoff (see Table S3).
Analyses of odds of ID produced a similar pattern of results
to those seen for ASD. Given the smaller number of ID cases,
these associations were not as precise as for ASD, but for all con-
geners higher levels were associated with reductions in odds of
ID, except for BB153 and BDE-28 (Table 5).
Analyses parameterizing BFR concentrations continuously
suggested generally null associations or modest reductions in
odds of ASD associated with higher BFR levels. With the
exception of BDE-153, which was associated with a 9% decrease
in odds of ASD with each 10-fold increase in serum concentra-
tion (AOR=0:91; 95% CI: 0.83, 0.99), these associations were
not statistically significant (Table 6). As for quartile analyses,
associations with ID were similar to those seen for ASD, with all
estimates below the null.
When examining BFRs in association with ASD with or with-
out intellectual disability, results were generally consistent with
those for ASD overall (see Table S4). Results were also stable
across various sensitivity analyses performed (see Table S5),
with point estimates and the pattern of results similar to primary
analyses when using uncensored laboratory data (numbers shown
in Table S6), multiple imputation to replace values <LOD,
removing the group of individuals originally classified as ID but
later determined to meet criteria for ASD, conducting matched
analyses using conditional logistic regression, or adding adjust-
ment for genetic ancestry PCs. Estimates were somewhat more
variable when removing individuals with values <LOD, espe-
cially for BDE-28 (as this congener had the greatest proportion
of individuals <LOD); however, point estimates remained below
the null. Due to the unexpected overall findings, we also explored
alternate paramterizations and categorizations of BFRs. Cubic
spline analyses suggested relationships between the congeners
and ASD, if any, were linear (and tests of nonlinearity were not
significant), with decreases in odds of ASD with higher BFR lev-
els that were not statistically significant except for BDE-153 (see
Figure S1). Examining high and low extremes of the distribution
of BFR concentrations relative to those with levels in the middle
range yielded results generally consistent with those suggested in
primary analyses, with nonsignificant reductions in odds of ASD
associated with BDEs in the >90th percentiles, and increases in
odds of ASD for those in the lowest 10th percentile (and particu-
larly lowest 5th percentile) of BDEs and the sum, as compared
with those with concentrations in the mid 11th–89th percentiles
(see Table S7).
Table 2. Serum brominated flame retardant (BFR) congener limit of detection information in the Early Markers for Autism study, by case status and sex.
BFR
Full study group (N= 1,144) nð%Þ>LOD %>LOD
LOD range Max lipid weight (ng/g) %>LOD ASD (n=545) ID (n=181) GP (n=418) Males (n=895) Females (n=249)
BB153 0.3–1.5 62.8 62 322 (63) 85 (53) 241 (63) 65 56
BDE-17 0.3–1.6 6.2 2 8 (2) 1 (1) 8 (2) 2 1
BDE-28 0.3–1.5 24.1 55 264 (53) 82 (53) 220 (59) 58 56
BDE-47 0.4–8.8 1000 98 534 (98) 178 (98) 410 (99) 98 99
BDE-66 0.3–1.6 9.4 1 7 (1) 0 8 (2) 1 2
BDE-85 0.3–1.7 44.3 39 177 (35)a 65 (41) 168 (44) 42 42
BDE-99 0.4–3.5 331 94 488 (92)a 167 (95) 390 (96) 94 95
BDE-100 0.3–2.3 271 95 497 (93)a 173 (98) 390 (96) 96 95
BDE-153 0.3–2.6 249 95 504 (95) 168 (95) 389 (96) 95 96
BDE-154 0.3–1.6 38.5 39 178 (35) 62 (39) 166 (43) 42 43
aSignificant difference in detection rates according to chi-squared test comparing ASD to GP. (No significant differences in detection rates were found comparing ID with GP.)
Table 3. Geometric mean brominated flame retardant congener serum concentrations (in ng/g lipid) and 95% confidence intervals from mid-pregnancy samples
in the Early Markers for Autism study by diagnostic group.
BFR
Full study group ASD ID GP ASD vs. GP ID vs. GP
n=1,144 n=545 n=181 n=418 p-Value p-Value
BB153 1.15 (1.09, 1.22) 1.21 (1.12, 1.31) 1.02 (0.90, 1.17) 1.14 (1.04, 1.25) 0.30 0.20
BDE-28 0.89 (0.85, 0.93) 0.87 (0.82, 0.92) 0.84 (0.77, 0.93) 0.94 (0.88, 1.02) 0.26 0.07
BDE-47 16.0 (15.1, 17.0) 14.7 (13.4, 16.0) 16.3 (14.2, 18.7) 17.9 (16.2, 19.7) 0.002 0.29
BDE-99 4.93 (4.63, 5.24) 4.45 (4.01, 4.87) 5.15 (4.47, 5.94) 5.52 (4.98, 6.11) 0.002 0.46
BDE-100 3.94 (3.71, 4.19) 3.59 (3.28, 3.93) 3.91 (3.45, 4.44) 4.48 (4.05, 4.95) 0.002 0.10
BDE-153 4.34 (4.08, 4.62) 4.02 (3.67, 4.40) 3.91 (3.41, 4.48) 5.02 (4.51, 5.58) 0.002 0.004
Suma 34.9 (32.9, 36.9) 32.1 (29.5, 34.9) 32.6 (28.6, 37.2) 40.1 (36.4, 44.2) 0.0006 0.02
Note: ASD, autism spectrum disorder; BDE, polybrominated diphenyl ether; GP, general population controls; ID, intellectual disability/developmental delay without autism. Table
shows geometric means following replacement of values <LOD with LOD divided by the square root of 2 as described in the text. For descriptive data by sex, see Table S8.
aSum is the sum of all congeners shown in table (e.g., those meeting our detection rate of at least 55% of the study population with concentrations >LOD).
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Results by Sex
As a consequence of original matching of ASD to GP, and
including individuals reclassified from ID to ASD following
expert review of records within our ASD analysis group (as
described in “Methods”), there were 99, 77, and 73 girls with
ASD, ID, and GP, respectively, and 446, 104, and 354 boys with
these outcomes (Table 1). Detection frequencies were similar
between male and female offspring (Table 2). Geometric mean
concentrations were higher for BDE congeners for ASD and ID
girls than for boys in these groups (see Table S8).
In analyses of ASD stratified by sex, ORs from quartile mod-
els of BB153 were generally close to the null and similar between
boys and girls (interaction p-value= 0:83, Table 7). Estimates for
all BDE congeners were below the null for boys (Table 7), and
comparing the highest to the lowest quartile, were significant for all
BDEs except BDE-28 (Figure 1). Overall, the estimates for boys
were consistent with those for the population as a whole, as
expected given that boys accounted for most of the ASD and GP
observations. In contrast, ORs comparing ASD in the highest and
lowest quartiles of BDE exposures in girls were above the null
(Figure 1). Interaction p-values were significant for all BDE conge-
ners, though estimates in girls were imprecise due to small numbers,
and patterns for lower quartiles were inconsistent (Table 7).
Differences in associations with ID between boys and girls
were generally consistent but less pronounced than those for
ASD (see Table S9). Comparing the highest to lowest quartiles,
estimates were above the null for girls for BDEs 47, 99, and 100,
and null for other congeners, and below the null for boys (Figure
2). Interaction terms for sex by congener levels for ID analyses
were not statistically significant (see Table S9).
Discussion
To our knowledge, this is the first study to examine prenatal BFR
exposure in association with ASD and ID. Contrary to expecta-
tions, ASD was inversely associated with the highest exposure
levels of several congeners, with significant inverse associations
estimated for BDE-100, -153, and the sum of BB153 and BDEs-
28, 47, -99, -100, and -153. Odds ratios for ID showed similar
patterns, but were less precise due to small numbers of cases, and
generally closer to the null. However, when we stratified by sex,
the inverse associations appeared to be specific to boys, whereas
associations for girls (though based on small numbers and thus
less precise) were more likely to be above the null.
To date, few other human studies have examined childhood
neurodevelopmental effects of prenatal BFR exposure, though
the majority of this literature suggests adverse impacts on child
Table 4. Odds ratios and 95% confidence intervals for associations between quartiles of prenatal brominated flame retardant serum concentrations and ASD
(relative to GP controls).
BFR/quartile PBDE concentrationa Caseb (n) Control (n) Model 1c Model 2d p-Trende
BB153
Q1 ≤0:5 114 93 1.0 1.0 0.86
Q2 0.51–1.06 124 92 1.10 (0.75, 1.61) 1.14 (0.76, 1. 70)
Q3 1.07–1.80 117 100 0.96 (0.65, 1.40) 0.86 (0.56, 1.31)
Q4 >1:80 154 98 1.28 (0.88, 1.86) 1.12 (0.73, 1.71)
BDE-28
Q1 ≤0:49 142 94 1.0 1.0 0.31
Q2 0.5–0.8 130 93 0.92 (0.64, 1.34) 0.95 (0.65, 1.39)
Q3 0.81–1.30 114 90 0.84 (0.57, 1.23) 0.89 (0.60, 1.31)
Q4 >1:3 116 99 0.77 (0.53, 1.13) 0.82 (0.56, 1.22)
BDE-47
Q1 ≤9:2 178 103 1.0 1.0 0.07
Q2 9.3–16.8 134 105 0.74 (0.52, 1.05) 0.77 (0.53, 1.10)
Q3 16.9–31.5 116 104 0.64 (0.45, 0.92) 0.71 (0.49, 1.02)
Q4 >31:5 117 104 0.65 (0.45, 0.93) 0.73 (0.50, 1.05)
BDE-99
Q1 ≤2:7 183 107 1.0 1.0 0.05
Q2 2.8–4.8 117 100 0.71 (0.50, 1.02) 0.75 (0.52, 1.08)
Q3 4.9–9.7 145 102 0.64 (0.44, 0.92) 0.72 (0.49, 1.04)
Q4 >9:7 88 98 0.61 (0.42, 0.87) 0.70 (0.48, 1.01)
BDE-100
Q1 ≤2:1 181 99 1.0 1.0 0.05
Q2 2.2–3.8 116 102 0.62 (0.43, 0.89) 0.66 (0.45, 0.95)
Q3 3.9–7.5 120 103 0.63 (0.44, 0.91) 0.68 (0.47, 0.98)
Q4 >7:5 116 103 0.61 (0.43, 0.88) 0.69 (0.47, 1.00)
BDE-153
Q1 ≤2:3 179 95 1.0 1.0 0.01
Q2 2.4–4.1 116 103 0.60 (0.42, 0.86) 0.62 (0.43, 0.90)
Q3 4.2–8.8 134 107 0.66 (0.46, 0.95) 0.71 (0.49, 1.03)
Q4 >8:8 104 102 0.54 (0.37, 0.78) 0.56 (0.38, 0.84)
Sumf 0.01
Q1 ≤20:2 166 94 1.0 1.0
Q2 >20:2–35:1 118 94 0.82 (0.58, 1.16) 0.83 (0.58, 1.18)
Q3 35.1–70.5 134 94 0.93 (0.66, 1.31) 1.01 (0.71, 1.44)
Q4 ≥70:5 84 94 0.58 (0.40, 0.84) 0.64 (0.44, 0.93)
Note: ASD, autism spectrum disorder; GP, general population controls.
aLipid-adjusted concentration in ng/g lipid, categorized into quartiles based on control distribution.
bColumns show number of cases and controls, respectively, in the quartile.
cModel 1: logistic regression adjusted for study matching factors (child sex, month and year of birth).
dModel 2: Model 1+maternal age (continuous), maternal race/ethnicity (non-Hispanic white, Asian, Black/Pacific Islander/or other, Hispanic, or Missing), maternal weight at time of
sample collection (quartiles), parity (multi- vs. primiparous), and maternal education (<high school, high school, college, graduate).
ep-Trend from model with quartile median-value variable, adjusted as Model 2.
fSum of all congeners shown in this table (those with at least 55% of study population with values >LOD).
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neurodevelopment (Herbstman and Mall 2014). In an analysis
including 323 mother–child pairs of the CHAMACOS (Center
for the Health Assessment of Mothers and Children of Salinas)
study (Eskenazi et al. 2013), a longitudinal birth cohort including
mostly Mexican-American families from California’s Salinas
Valley, individuals with the highest quartiles of the sum of 10
PBDEs measured in prenatal serum samples (including some
congeners not included in our analysis) had lower attention, fine
motor, and verbal comprehension scores at 5 or 7 y. Another
study, conducted in Spain, reported nonsignificant inverse associ-
ations between pre- (measured in cord blood, n=88) and post-
natal (measured in child serum at age 4, n=244) BDE-47 levels
when comparing those above with those below the limit of detec-
tion and cognitive and motor scores as measured by the
McCarthy Scales at age 4 (Gascon et al. 2011). Additional work
by the same group suggested an inverse association between
scores on the Bayley Scales of Infant Development and BDE-209
concentrations measured in colostrum (Gascon et al. 2012). In
another study of mothers and children from New York, increases
in levels of PBDEs (particularly BDE-47, -99, and -100)
measured in cord blood (n=210) were associated with decreases
in psychomotor and mental development scores at 12, 24, and 36
mo, and with lower IQ scores at 48 mo (Herbstman et al. 2010).
However, findings have not been consistent across all studies.
In an analysis of the Pregnancy, Infection, and Nutrition study of
North Carolina including 304 mothers and their children, individ-
uals in the highest quartiles of PBDEs measured in breast milk
(including the same BDE congeners included in analyses in our
study) had higher scores for anxious behavior, but also higher
adaptive and cognitive behavior scale scores as measured by the
parent rating scale for preschoolers (age 2–5 y) of the Behavior
Assessment System for Children, 2nd Edition (BASC-2), relative
to those in the lowest quartile of PBDE congeners (Adgent et al.
2014). In the only study other than ours to our knowledge with
prenatal PBDE measurements and ASD outcome information
(Braun et al. 2014), the HOME Study (Health Outcomes and
Measures of the Environment Study), which includes over 400
pregnant women and their children from the Cincinnati, Ohio,
area, reported conflicting findings for different congeners meas-
ured in prenatal serum samples from 175 of its participants.
Increases in BDE-28 were associated with higher SRS scores
(indicating more autistic behaviors), and detectable versus nonde-
tectable concentrations of BDE-85 were associated with fewer
autistic behaviors. Six other PBDE congeners in the HOME
Study had close to null, nonsignificant associations with SRS
scores. In another analysis in the HOME Study including 309
participants, a 10-fold increase in BDE-47 was associated with a
significantly lower full-scale IQ and significantly higher hyperac-
tivity score at age 5 y, but there were no significant associations
for younger ages examined (Chen et al. 2014a). Differences in
study populations, or design (e.g., measuring PBDEs in prenatal
serum vs. breast milk) may have contributed to discrepancies in
prior literature. California is known to have some of the highest
reported serum levels of PBDEs worldwide. Although the levels
detected in our study population were lower than some other stud-
ies of pregnant women in California and elsewhere (Woodruff
et al. 2011; Buttke et al. 2013; Zota et al. 2013), they were similar
to those reported in CHAMACOS (also a California study of
Table 6. Odd ratios and 95% confidence intervals for associations of ASD
and ID (relative to GP controls) with 10-fold increases in brominated flame
retardant concentrations from maternal serum samples (ng/g lipid).
BFR Adjusted Model 1a Adjusted Model 2b p-Valuec
ASD
BB153 1.00 (0.75, 1.33) 0.97 (0.73, 1.30) 0.85
BDE-28 0.54 (0.25, 1.19) 0.58 (0.26, 1.27) 0.17
BDE-47 0.98 (0.96, 1.00) 0.99 (0.97, 1.01) 0.19
BDE-99 0.97 (0.92, 1.01) 0.97 (0.93, 1.02) 0.24
BDE-100 0.94 (0.86, 1.02) 0.95 (0.87, 1.02) 0.17
BDE-153 0.91 (0.83, 0.99) 0.91 (0.83, 0.99) 0.02
Sumd 0.99 (0.98, 1.00) 0.99 (0.98, 1.00) 0.10
ID
BB153 0.74 (0.37, 1.49) 0.98 (0.55, 1.75) 0.95
BDE-28 0.23 (0.04, 1.24) 0.24 (0.04, 1.25) 0.09
BDE-47 0.98 (0.95, 1.02) 0.98 (0.95, 1.02) 0.27
BDE-99 0.95 (0.87, 1.03) 0.94 (0.87, 1.03) 0.17
BDE-100 0.83 (0.68, 1.02) 0.84 (0.68, 1.04) 0.11
BDE-153 0.81 (0.67, 0.99) 0.88 (0.73, 1.07) 0.21
Sumd 0.98 (0.95, 1.00) 0.98 (0.95, 1.00) 0.09
aModel 1: logistic regression adjusted for study matching factors (child sex, month and
year of birth).
bModel 2: Model 1 +maternal age (continuous), maternal race/ethnicity (non-Hispanic
white, Asian, Black/Pacific Islander/or other, Hispanic, or Missing), maternal weight at
time of sample collection (quartiles), parity (multi- vs. primiparous), and maternal edu-
cation (<high school, high school, college, graduate).
cp-Value for BFR coefficient from adjusted model 2.
dSum of all congeners shown in this table (e.g., those with at least 55% of study popula-
tion with values >LOD).
Table 5. Odds ratios and 95% confidence intervals for associations between
quartiles of prenatal brominated flame retardant serum concentrations and
ID (relative to GP controls).
BFR/quartile
ID
(n)
Control
(n) Model 1a Model 2b p-Trendc
BB153
Q1 41 93 1.0 1.0 0.62
Q2 52 92 1.21 (0.72, 2.05) 1.46 (0.84, 2.54)
Q3 30 100 0.71 (0.40, 1.26) 0.95 (0.51, 1.79)
Q4 37 98 0.84 (0.48, 1.45) 1.34 (0.72, 2.51)
BDE-28
Q1 38 94 1.0 1.0 0.95
Q2 47 93 1.24 (0.72, 2.13) 1.30 (0.73, 2.31)
Q3 34 90 0.97 (0.55, 1.73) 1.00 (0.54, 1.82)
Q4 36 99 1.06 (0.60, 1.86) 1.12 (0.62, 2.04)
BDE-47
Q1 46 103 1.0 1.0 0.30
Q2 52 105 1.09 (0.66, 1.81) 1.04 (0.62, 1.77)
Q3 48 104 1.06 (0.63, 1.77) 0.93 (0.54, 1.58)
Q4 35 104 0.81 (0.47, 1.38) 0.76 (0.43, 1.34)
BDE-99
Q1 46 107 1.0 1.0 0.14
Q2 46 100 0.93 (0.56, 1.55) 0.87 (0.51, 1.49)
Q3 48 102 1.06 (0.64, 1.78) 0.85 (0.50, 1.46)
Q4 36 98 0.75 (0.44, 1.29) 0.64 (0.36, 1.13)
BDE-100
Q1 46 99 1.0 1.0 0.55
Q2 45 102 0.89 (0.53, 1.50) 0.86 (0.50, 1.48)
Q3 50 103 1.07 (0.65, 1.79) 1.02 (0.60, 1.73)
Q4 35 103 0.77 (0.45, 1.32) 0.78 (0.44, 1.37)
PBDE153
Q1 53 95 1.0 1.0 0.56
Q2 48 103 0.93 (0.56, 1.53) 1.01 (0.60, 1.70)
Q3 41 107 0.74 (0.44, 1.24) 0.83 (0.49, 1.42)
Q4 34 102 0.71 (0.41, 1.20) 0.90 (0.51, 1.62)
Sumd
Q1 45 94 1.0 1.0 0.14
Q2 42 94 0.84 (0.52, 1.37) 0.87 (0.52, 1.43)
Q3 44 94 0.91 (0.56, 1.47) 0.87 (0.53, 1.43)
Q4 24 94 0.53 (0.31, 0.92) 0.58 (0.33, 1.03)
Note: GP, general population controls; ID, intellectual disability/developmental delay
without autism.
aModel 1: logistic regression adjusted for study matching factors (child sex, month and
year of birth).
bModel 2: Model 1+maternal age (continuous), maternal race/ethnicity (non-Hispanic
white, Asian, Black/Pacific Islander/or other, Hispanic, or Missing), maternal weight at
time of sample collection (quartiles), parity (multi- vs. primiparous), and maternal edu-
cation (<high school, high school, college, graduate, missing).
cp-Trend from the median value variable, adjusted as Model 2.
dSum of all congeners shown in this table (those with at least 55% of study population
with values >LOD).
Environmental Health Perspectives 087023-7
pregnant women) (Eskenazi et al. 2013), as well as the HOME
Study (in Ohio) (Braun et al. 2014).
The reason for an inverse association between prenatal BFRs
and odds of ASD as suggested for some congeners here is not
apparent. While adjustment for a large number of factors, includ-
ing demographic characteristics shown to be predictive of PBDE
levels (Horton et al. 2013), as well as genetic PCs, did not materi-
ally change our results, it is possible that inverse associations
may be due to unmeasured confounding by some shared influen-
ces on BFR levels and ASD, rather than a true protective associa-
tion. If higher levels of flame retardants are associated with
spontaneous abortion, as suggested in one study of polybromi-
nated biphenyls (Small et al. 2011), this may have influenced the
observed associations, particularly if male fetuses are more sus-
ceptible to such loss—though this is not clear (Orzack et al.
2015). It is also possible that such findings are due to chance.
Results here could also be consistent with an overall lack of an
association with ASD, as suggested by nonsignificant results of
continuous analyses for most congeners and some of our sensitiv-
ity analyses.
Null findings in other work, along with results here, suggest
that prenatal exposure to these BFRs may be unrelated to ASD
risk specifically. However, prenatal exposure may influence fre-
quently comorbid features of ASD, such as attention deficits or
related impairments in cognitive scores, and these questions
should be further explored. Other than examining comorbid ID,
we did not have the ability to assess the influence of heterogene-
ity within ASD, or risk of ASD with other comorbid conditions,
and associations could plausibly vary according to phenotypically
distinct ASD subgroups.
When examining associations stratified by sex, our study
found significant inverse associations with higher brominated
PBDEs (BDE-100, -153) in boys, and nonsignificant increases in
odds of ASD (particularly for BDE-28, -47) when comparing
high with low quartiles of BDEs in girls. In addition, significant
interactions with sex were suggested for all BDE congeners.
However, patterns over all quartiles were not consistent with
monotonic trends, and estimates in girls were imprecise. We can-
not place too much emphasis on the results for individual conge-
ners in our stratified analyses, given the high correlation of most
PBDE congeners, as well as the smaller numbers of girls in our
study as a result of the skewed sex ratio in ASD. However, sex
differences in placental functioning (Rosenfeld 2015), pharmaco-
kinetics, or methylation patterns, supported in prior work (Soldin
and Mattison 2009; Huen et al. 2014) could result in sex-specific
effects of BFRs on fetal development. The suggestion of sex dif-
ferences seen here warrants further consideration, particularly in
light of toxicologic evidence from animal models of potential
sexually dimorphic effects of these chemicals (Lilienthal et al.
2006; Woods et al. 2012; Faass et al. 2013), as well as the
Table 7. Odds ratios and 95% confidence intervals for quartiles of prenatal brominated flame retardant congener serum concentrations in association with ASD
(relative to GP controls), stratified by child sex.
BFR/quartile
Males Females
p-InteractionaCase/control (n/n) Model 1b Model 2c Case/control (n/n) Model 1 Model 2
BB153 0.83
Q1 93/76 1.0 1.0 21/17 1.0 1.0
Q2 95/74 1.05 (0.68, 1.61) 1.12 (0.72, 1. 75) 29/18 1.32 (0.55, 3.18) 1.27 (0.48, 3.37)
Q3 100/85 0.96 (0.63, 1.46) 0.85 (0.53, 1.36) 17/15 0.93 (0.36, 2.40) 0.99 (0.31, 3.20)
Q4 130/81 1.31 (0.87, 1.99) 1.10 (0.72, 1. 69) 24/17 1.17 (0.47, 2.89) 1.19 (0.37, 3.78)
BDE-28 0.02
Q1 122/76 1.0 1.0 20/18 1.0 1.0
Q2 104/74 0.87 (0.58, 1.32) 0.94 (0.61, 1.44) 26/19 1.23 (0.52, 2.96) 0.92 (0.34, 2.46)
Q3 95/72 0.82 (0.54, 1.25) 0.91 (0.59, 1.40) 19/18 0.96 (0.39, 2.41) 0.70 (0.25, 2.00)
Q4 92/89 0.64 (0.42, 0.97) 0.70 (0.45, 1.07) 24/10 2.20 (0.82, 5.92) 2.58 (0.86, 7.79)
BDE-47 0.02
Q1 152/81 1.0 1.0* 26/22 1.0 1.0+
Q2 108/89 0.64 (0.44, 0.95) 0.70 (0.47, 1.04) 26/16 1.37 (0.59, 3.19) 1.31 (0.50, 3.43)
Q3 95/82 0.61 (0.41, 0.92) 0.69 (0.47, 1.00) 21/22 0.78 (0.34, 1.81) 0.89 (0.34, 2.31)
Q4 91/91 0.53 (0.36, 0.79) 0.72 (0.50, 1.05) 26/13 1.66 (0.69, 4.00) 2.64 (0.97, 7.19)
BDE-99 0.04
Q1 150/80 1.0 1.0* 27/20 1.0 1.0
Q2 111/85 0.69 (0.47, 1.03) 0.74 (0.50, 1.11) 19/18 0.77 (0.32, 1.85) 0.86 (0.32, 2.30)
Q3 87/83 0.55 (0.37, 0.83) 0.61 (0.40, 0.93) 29/19 1.13 (0.50, 2.58) 1.81 (0.70, 4.69)
Q4 88/88 0.53 (0.36, 0.79) 0.60 (0.39, 0.90) 22/14 1.16 (0.48, 2.82) 1.98 (0.71, 5.56)
BDE-100 0.03
Q1 151/80 1.0 1.0* 30/19 1.0 1.0
Q2 101/81 0.66 (0.44, 0.98) 0.72 (0.48, 1.08) 15/21 0.45 (0.19, 1.08) 0.51 (0.19, 1.38)
Q3 92/86 0.57 (0.38, 0.84) 0.61 (0.40, 0.91) 28/17 1.05 (0.45, 2.44) 1.56 (0.59, 4.17)
Q4 92/89 0.55 (0.37, 0.81) 0.61 (0.40, 0.92) 24/14 1.09 (0.45, 2.62) 1.62 (0.59, 4.42)
BDE-153 0.02
Q1 152/72 1.0 1.0* 27/23 1.0 1.0
Q2 90/88 0.48 (0.32, 0.73) 0.48 (0.32, 0.73) 26/15 1.48 (0.64, 3.44) 2.12 (0.82, 5.52)
Q3 111/87 0.61 (0.41, 0.90) 0.64 (0.43, 0.97) 23/20 0.96 (0.42, 2.20) 1.20 (0.45, 3.23)
Q4 83/89 0.44 (0.29, 0.67) 0.45 (0.29, 0.70) 21/13 1.35 (0.55, 3.31) 2.04 (0.71, 5.84)
Sumd 0.03
Q1 143/75 1.0 1.0* 29/20 1.0 1.0
Q2 90/78 0.79 (0.54, 1.16) 0.82 (0.55, 1.22) 22/17 0.94 (0.42, 2.09) 1.03 (0.41, 2.59)
Q3 117/78 0.92 (0.63, 1.35) 1.02 (0.69, 1.50) 22/17 0.91 (0.41, 2.05) 1.28 (0.51, 3.20)
Q4 68/85 0.52 (0.35, 0.78) 0.57 (0.37, 0.86) 16/11 1.04 (0.42, 2.57) 1.42 (0.51, 3.98)
Note: GP, general population.
ap-Interaction term for BFR concentration (ordinal median value variable) by sex, adjusted as in Model 2, including males and females.
bModel 1: logistic regression adjusted for child month and year of birth.
cModel 2 (estimates as shown in Figure 1): Model 1 +maternal age, maternal race/ethnicity, maternal weight at time of sample collection, parity, and maternal education.
dSum of congeners listed in table (detected in >55% of the study population). *p<0:05 in test for trend across quartiles.
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consistent male-skewed sex ratio for ASD suggesting that risk
factors that differ by sex may provide etiologic clues.
In support of such dimorphism, previous studies have sug-
gested sex differences in the effects of prenatal BFR exposure on
other outcomes. Associations with child BMI at age 7 y (Erkin-
Cakmak et al. 2015), birth weight (Robledo et al. 2015), and de-
velopment of sexually dimorphic brain regions in the rat (Faass
et al. 2013) were all in opposite directions for males and females.
In addition, some studies have suggested developmental impacts
in girls, but not boys, in association with other EDCs. In the
HOME Study (described above), a stronger association between
prenatal bisphenol A exposure measured in maternal samples col-
lected at 16 wk gestation and externalizing behavior at age 2 was
noted for girls (Braun et al. 2009), though associations were not
significant at other time points. Another analysis of the same
cohort and maternal serum samples found that only in girls were
there greater social deficits with higher levels of one of five pre-
natal organochlorine pesticides (another class of EDCs) exam-
ined (Braun et al. 2014). Of over 50 EDCs evaluated, few other
sex differences, not all in the same direction, were reported in
this study: a positive association with autistic traits as measured
by the SRS and serum perfluorooctanesulfonic acid in boys but
Figure 1. Adjusted odds ratio (AOR) estimates from logistic regression for ASD relative to GP comparing those with in highest quartile of the BFR congener
levels to the lowest (referent) quartile, adjusted for maternal age, education, race/ethnicity, weight, parity, and child year and month of birth (e.g., as in Table 3
Model 2, without adjustment for child sex). Diamonds (boys, n=446 ASD cases and 345 GP controls) and circles (girls, n=99 ASD cases and 73 GP con-
trols). Vertical lines indicate 95% confidence intervals. Horizontal line indicates the null value of OR=1. The y axis is log-scaled for symmetry. Numbers of
observations, AORs, and 95% confidence intervals for all quartiles are shown in Table 7. Sum indicates the sum of congeners shown (those with at least 55%
of study population with values >LOD).
Figure 2. Adjusted odds ratio (AOR) estimates for ID relative to GP, adjusted for maternal age, education, race/ethnicity, weight, parity, and child year and
month of birth. Diamonds (boys, n=104 ID cases and 345 GP controls) and circles (girls, n=77 ID cases and 73 GP controls). Vertical lines indicate 95%
confidence intervals. Horizontal line indicates the null value of OR=1. The y axis is log-scaled for symmetry. Numbers of observations, AORs, and 95% confi-
dence intervals for all quartiles are shown in Table S7. Sum indicates the sum of congeners shown (those with at least 55% of study population with values
>LOD).
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not girls, and opposing relationships with SRS scores in boys
(negative) and girls (positive) with levels of monoethyl phthalate.
Suspected pathways through which BFRs may influence neu-
rodevelopment include disruptions of immune markers, neuro-
transmitters, or calcium signaling (Hendriks et al. 2010; Grandjean
and Landrigan 2014) and through impacts on thyroid hormone lev-
els, which play a known role in neurodevelopment (de Escobar
et al. 2004). There is limited animal evidence suggesting that
impacts on thyroid hormone levels following exposure to other
chemicals may differ between the sexes (Sulkowski et al. 2012).
Some studies have reported associations between thyroid hormone
(Vuong et al. 2015) or immune markers (Ashwood et al. 2009)
and PBDEs only for those congeners (-28 and -47) for which we
saw the strongest suggestion for an association with ASD in girls,
though these findings are not uniform, with other studies reporting
null or nonsignificant associations between PBDE congeners and
thyroid hormones, and no differences by sex (Chevrier et al. 2011;
Liu et al. 2012; Eggesbø et al. 2011; Gascon et al. 2011; Eskenazi
et al. 2013). Thus, work examining mechanisms by which these
chemicals may influence neurodevelopment in humans is still
needed and may help elucidate associations.
This study has a number of strengths: measurement of BFR
levels during gestation, a time period demonstrated to be critical
to neurodevelopment (Rodier et al. 1996; Rice and Barone 2000),
inclusion of over 500 cases of ASD, and ASD and ID diagnoses
confirmed by expert clinician review. However, certain limita-
tions should be noted. A number of congeners were not detected
in enough of our study group in order to examine their associa-
tion with the outcomes of interest, though detection rates
(%>LOD) were similar to those reported in other studies
(Chevrier et al. 2011; Adgent et al. 2014). We lacked information
on exposure in other time windows, including during breastfeed-
ing, which, although potentially highly correlated with mid-
gestational exposure levels (Makey et al. 2014), could also repre-
sent critical windows of exposure for ASD and ID risk. Though
our sample size was adequate in primary analyses, we had
reduced power in analyses of ASD and ID in females. We did not
have information on income level, though adjustment for avail-
able socioeconomic status (SES)-related variables in our study
(maternal education, race/ethnicity, insurance status at delivery,
and maternal birth outside the United States) did not alter our
results. Concerns regarding confounding by SES may be lower in
this population-based study relative to clinic-based samples.
However, our study population, although comparable to its
source population of California (Kharrazi et al. 2012) with a high
proportion of Hispanics and individuals on government-funded
insurance relative to the general U.S. population, may have
reduced generalizability to some other regions. We did not have
information on maternal IQ, a predictor of child IQ, though we
did adjust for maternal education. We also cannot rule out poten-
tial ID misclassification, given that ID was determined only
according to available standardized test scores in diagnostic
records; however, such records were reviewed by a trained clini-
cian. We did not have the ability to examine the influence of cer-
tain pregnancy complications such as gestational diabetes or
changes in body mass index, factors that may influence bioavaila-
bility of these compounds and may put an individual at higher
risk for ASD; however, we did adjust for maternal weight at
blood sample collection. It is likely that the influence of BFR ex-
posure could vary by genetics; thus, additional consideration of
how genetics influences the impact of these exposures is war-
ranted. Finally, though we examined adjustment for exposure to
PCBs, and this did not alter findings, future work should consider
employing the emerging methodologies to handle exposure to
mixtures of chemicals.
Conclusions
The primary analyses of this study did not support the hypothesis
that prenatal PBDEs increase risk of ASD or ID. Results overall
suggested a lack of an association to reductions in odds of ASD
and ID with higher levels of BFRs, particularly for ASD in chil-
dren born to mothers with levels of certain BDEs in the highest
quartile relative to those with levels in the lowest quartile.
However, findings from stratified analyses suggested the potential
for effect modification by child sex, with the inverse associations
for exposure to higher levels of prenatal PBDEs observed in
boys. Associations in the opposite direction were suggested for
girls, but we lacked precision in these estimates owing to smaller
numbers. Given limited human studies on the developmental
effects of exposure to these ubiquitous chemicals, continued
investigation is needed. Future work with sufficient numbers of
male and female cases should confirm whether associations seen
here are replicated and investigate whether PBDEs are associated
with developmental disorders, and ASD in particular, through
sexually dimorphic pathways.
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